Reviva Pharmaceuticals Holdings, Inc.
RVPH OTC
SEC CIK 1742927
Follow Reviva Pharmaceuticals
Weekly email: filings, results, news
Net income
−$2.4M
+59.6% vs same quarter last year
EPS, diluted
−$0.19
+92.1% vs same quarter last year
Operating cash flow
−$2.1M
+57.8% vs same quarter last year
Operating income
−$2.6M
+56.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$19.9M |
| FY24 | −$29.9M |
| FY23 | −$39.3M |
| FY22 | −$28.3M |
| FY21 | −$8.5M |
| FY20 | −$3.8M |
| FY19 | −$846.8K |
| FY18 | - |
News
No stories filed under Reviva Pharmaceuticals yet - coverage appears here as the news feed clusters it.